Prescribing information is available here. Adverse Event reporting can be found in the footer.
Kinpeygo®▼
Kinpeygo® indication update
Kinpeygo is now indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).1
UK RaDaR data shows that 50% of IgA nephropathy patients will reach kidney failure or death within 10-15 years.2
Kinpeygo® – the first and only disease-modifying treatment for use in IgA nephropathy.1
Kinpeygo is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g).1
Prescribing Information can be found here and Adverse Event reporting information can be found in the footer
Find out more about Kinpeygo®
Request a visit from our Medical Science Liaison Team or Healthcare Partnership Manager Team
How to order Kinpeygo®
Order via HealthNet Homecare for delivery to your Trust or direct to your patient.
Patient insight | Nov 2023
Patient experts help gain NICE approval for new IgA nephropathy treatment
Ben Stokes, 35 from Maidenhead, was part of an expert panel of patients who shared their insight with decision makers on the life-changing impact that budesonide could have for people living with IgA nephropathy.
In an article on Kidney Research UK, Ben said, “I wish this medication had been available 10 years ago and then I might not be in the position that I’m in now. Somebody that might have taken ten years like me to get to end stage kidney function could take 20 or 30 years, or not ever get there”.
Clinical Resource:
Kinpeygo®
Kinpeygo®
NICE Guidance
Kinpeygo®
Pharmacy Leaflet
Kinpeygo®
Clinician Guide
Educational Webinars
Kinpeygo® Patient Support Leaflet
Understanding IgA Nephropathy Leaflet
Visit the Kinpeygo® Patient Website
Let’s stay connected!
Want to be the first to hear about the products, services and educational resources we offer, including invitations to webinars and events?
References
1. Kinpeygo® 4 mg modified release hard capsules. Summary of product characteristics. Available at:https://www.medicines.org.uk/emc/product/15393/smpc. Last accessed: June 2025. 2. Pitcher D et al. (2023). CJASN.18(6):727-738.
Information
For information on our products please visit EMC, https://www.medicines.org.uk/emc/ and search the product for a Summary of Product Characteristics
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Thornton and Ross Limited by emailing thorntonross@medinformation.co.uk or by calling 01484 848164.
UK-MULT-122e(6) | June 2025